AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04383717
Drug: Levamisole and isoprinosine
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
Trial: NCT04383717
Drug: Azithromycin and hydroxychloroquine
RxNorm normalized name: cefixime and azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
Trial: NCT01151449
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00004424
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00925873
Drug: Experimental (fludarabine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2.
Trial: NCT01909739
Drug: atrovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Trial: NCT01909739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Trial: NCT03225352
Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intake of 1 tablet, 500mg
Trial: NCT03225352
Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intake of 1 tablet, 1000mg
Trial: NCT03225352
Drug: 400 mg ibuprofen(Nurofen)
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intake of 1 tablet, 400mg
Trial: NCT03225352
Drug: 400 mg ibuprofen (Dolormin Extra)
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intake of 1 tablet, 400mg
Trial: NCT00089427
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01740791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT02686762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
Trial: NCT00650273
Drug: Azithromycin Tablets 600 mg
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, single dose fasting
Trial: NCT00650273
Drug: Zithromax® Tablets 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg, single dose fasting
Trial: NCT02690935
Drug: 2LALERG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic drug
Trial: NCT02690935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02123524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00800618
Drug: PF-02413873 100 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of PF-02413873 oral suspension once daily for 14 days
Trial: NCT00800618
Drug: PF-02413873 500 mg QD
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of PF-02413873 oral suspension once daily for 14 days
Trial: NCT00800618
Drug: PF-02413873 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-0241383 Placebo once daily for 14 days
Trial: NCT06048887
Drug: CRN04894 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Trial: NCT06048887
Drug: Placebo Oral Solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03187587
Drug: Standard chemotherapy treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard chemotherapy treamtment arm recieves only chemotherapy.
Trial: NCT02997722
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 100 ml of normal saline over 45 minutes.
Trial: NCT00032916
Drug: NS2359
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000425
Drug: Nonsteroidal anti-inflammatory drugs (NSAIDs)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000425
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00176930
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
Trial: NCT02674386
Drug: Investigational Medical Product (IMP) administered in parent study
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
Trial: NCT00476593
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
Trial: NCT00004188
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00004188
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03171623
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administration, single dose
Trial: NCT00807209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
Trial: NCT00807209
Drug: Fentanyl via PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl via PCA
Trial: NCT01040793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Trial: NCT02094261
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tablet 80 mg
Trial: NCT00337987
Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
Trial: NCT00373425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00351286
Drug: Background simvastatin at a stable dose of 40 mg qHS
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00311220
Drug: tuberculin for skin test
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01242644
Drug: ropivacaine, ketorolac , morphine sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
Trial: NCT01666977
Drug: AMG 386 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 Placebo
Trial: NCT01097551
Drug: Iontophoresis with acetylcholine delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with acetylcholine delivery
Trial: NCT02093923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo subcutaneously.
Trial: NCT01195116
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mcg/kg/hr
Trial: NCT04640012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered
Trial: NCT01065116
Drug: AL Blister-packs with Instruction leaflets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL Blister packs with instruction leaflets will be dispensed
Trial: NCT00277043
Drug: taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
Trial: NCT00825864
Drug: diclofenac drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop 4 times a day for 3 months
Trial: NCT00500318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo, once daily oral inhalation.
Trial: NCT00223938
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron
Trial: NCT00945334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 14 days tid
Trial: NCT00458107
Drug: SCA-136
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01813435
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
Trial: NCT01497119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=tablet, route=oral use, once daily for 6 weeks.
Trial: NCT02332005
Drug: diepalrestat choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aldose reductase inhibitor
Trial: NCT03429049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving Placebo injection
Trial: NCT02656251
Drug: 0.12% Clorhexidine with alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
Trial: NCT02656251
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo every 12 hours for 04 days
Trial: NCT02656251
Drug: 0.12% Clorhexidine without alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
Trial: NCT00996424
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation with normal saline solution
Trial: NCT04478708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
Trial: NCT02992457
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three months in repeated treatment failure
Trial: NCT04459676
Drug: Standard of Care (SOC) + ANG-3777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) + ANG-3777
Trial: NCT04459676
Drug: Standard Of Care (SOC) + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Of Care + Placebo
Trial: NCT00099580
Drug: AC2592
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight
Trial: NCT00804245
Drug: PET-CT scans supplemented with 11C-Choline tracer
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
Trial: NCT00108667
Drug: IV Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03963362
Drug: GLA5PR tablet 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLARS-NF3 tablet
Trial: NCT03963362
Drug: GLA5PR tablet 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLARS-NF3 tablet
Trial: NCT00631007
Drug: INT131 besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, oral
Trial: NCT00631007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, oral
Trial: NCT01231373
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of vehicle comparator
Trial: NCT02328755
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
Trial: NCT00263887
Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
Trial: NCT03211455
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous isotonic saline
Trial: NCT04053673
Drug: RBN-2397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an oral PARP7 Inhibitor
Trial: NCT03129776
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
Trial: NCT02913131
Drug: Pyruvate (13C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyruvate injection followed by an MRI scan.
Trial: NCT04481750
Drug: MT-1186-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution or suspension
Trial: NCT03263442
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg IV three times daily for seven days
Trial: NCT03263442
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV three times daily for seven days
Trial: NCT01858922
Drug: DECA
RxNorm normalized name: Decara
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion.
Trial: NCT01618513
Drug: Sandostatin® LAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections, dosage based on either GH or IGF-I levels.
Trial: NCT03838133
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
Trial: NCT03838133
Drug: Naropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
Trial: NCT03838133
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% sodium chloride, 10ml)
Trial: NCT02715232
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
Trial: NCT02715232
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
Trial: NCT01139294
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
Trial: NCT02675374
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 minutes before CPB, patients will receive 2 ml of normal saline
Trial: NCT03314363
Drug: NaCl predilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replace citrate predilution with NaCl
Trial: NCT03314363
Drug: double ultrafiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
Trial: NCT01431833
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose 200 mg
Trial: NCT01544517
Drug: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
Trial: NCT01558830
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
Trial: NCT01669824
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
Trial: NCT00096239
Drug: CP-547,632
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03769831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose oral adminstration
Trial: NCT03017950
Drug: D086
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01362673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose as matching placebo
Trial: NCT01362673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral multiple doses as matching placebo for 12 days
Trial: NCT01688882
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
Trial: NCT01034462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Trial: NCT01688882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be used to control for normal variability in disease severity.
Trial: NCT03011060
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
Trial: NCT03255044
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin administered as well as standard heart failure therapy
Trial: NCT00267358
Drug: RC-1291 HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00267358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01334957
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Trial: NCT00873834
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized
Trial: NCT00873834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.